---
figid: PMC10522837__fphar-14-1247664-g005
pmcid: PMC10522837
image_filename: fphar-14-1247664-g005.jpg
figure_link: /pmc/articles/PMC10522837/figure/F5/
number: FIGURE 5
figure_title: ''
caption: 'cAMP/PKA pathway and AMPK activation in the presence of dipyridamole.(A)
  cAMP levels in myoblasts (left) and myotubes (right). (B) Study of protein expression
  of PKAα, PKAβ, PKAγ, pCREB and EPAC 1 and 2. Data are representative of n = 5 each
  group per day (mean ± SEM).*: treatment group vs. control group; #: treatment group
  vs. tenofovir group. T + D: tenofovir + dipyridamole; DD: days of differentiation.'
article_title: Dipyridamole activates adenosine A2B receptor and AMPK/cAMP signaling
  and promotes myogenic differentiation of myoblastic C2C12 cells.
citation: Miguel Marco-Bonilla, et al. Front Pharmacol. 2023;14:1247664.
year: '2023'

doi: 10.3389/fphar.2023.1247664
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.

keywords:
- adenosine
- A2B receptor
- muscle
- sarcopenia
- dipyridamole

---
